Treatment of travelers' diarrhea: Randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone

被引:58
作者
DuPont, Herbert L.
Jiang, Zhi-Dong
Belkind-Gerson, Jaime
Okhuysen, Pablo C.
Ericsson, Charles D.
Ke, Shi
Huang, David B.
Dupont, Margaret W.
Adachi, Javier A.
de la Cabada, F. Javier
Taylor, David N.
Jaini, Sridvya
Sandoval, Francisco Martinez
机构
[1] Univ Texas, Sch Publ Hlth, Ctr Infect Dis, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Div Mol Imaging, Houston, TX 77030 USA
[4] St Lukes Episcopal Hosp, Houston, TX 77030 USA
[5] Inst Nacl Salud Publ Mexico, Cuernavaca, Morelos, Mexico
[6] Univ Texas, MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA
[7] Hosp Gen Occidente Seguro Social, Zapopan, Mexico
[8] Salix Pharmaceut Inc, Morrisville, NC USA
[9] Univ Autonoma Guadalajara, Guadalajara, Jalisco, Mexico
关键词
D O I
10.1016/j.cgh.2007.02.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Antimotility agents provide rapid temporary relief of acute diarrhea, whereas antibiotics slowly cure the illness. Thus, the combination of an antimotility agent and an antibiotic may provide greater therapeutic benefit than either drug alone. This study evaluated the efficacy and safety of rifaximin-loperamide in the treatment of travelers' diarrhea. Methods: Consenting adults with acute diarrhea ( >= 3 unformed stools in 24 hours with >= 1 symptom of enteric infection) were randomized to receive rifaximin 200 mg 3 times daily for 3 days; loperamide 4 mg initially followed by 2 mg after each unformed stool; or a combination of both drugs using the same dosing regimen. The primary end point was the median time from beginning therapy until passing the last unformed stool. Results: A total of 310 patients completed treatment with rifaximin (n = 102), loperamide (n = 104), or rifaximin-loperamide combination therapy (n = 104). The groups showed demographic similarity. Rifaximin and rifaximin-loperamide significantly reduced the median time until passage of the last unformed stool (32.5 +/- 4.14 h and 27.3 +/- 4.13 h, respectively) vs loperamide (69 +/- 4.11 h; P =.0019). The mean number of unformed stools passed during illness was lower with rifaximin-loperamide (3.99 +/- 4.28) compared with rifaximin (6.23 +/- 6.90; P =.004) or loperamide alone (6.72 +/- 6.93; P =.002). All treatments were well tolerated with a low incidence of adverse events. Conclusions: Rifaximin-loperamide therapy provided rapid symptomatic improvement and greater overall wellness compared with either agent alone.
引用
收藏
页码:451 / 456
页数:6
相关论文
共 33 条
[1]   Traveler's diarrhea: Modern concepts and new developments [J].
DuPont A.W. ;
DuPont H.L. .
Current Treatment Options in Gastroenterology, 2006, 9 (1) :13-21
[2]   COMPARATIVE EFFICACY OF LOPERAMIDE HYDROCHLORIDE AND BISMUTH SUBSALICYLATE IN THE MANAGEMENT OF ACUTE DIARRHEA [J].
DUPONT, HL ;
SANCHEZ, JF ;
ERICSSON, CD ;
GOMEZ, JM ;
DUPONT, MW ;
LUNA, AC ;
MATHEWSON, JJ .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (6A) :S15-S19
[3]   5 VERSUS 3 DAYS OF OFLOXACIN THERAPY FOR TRAVELERS DIARRHEA - A PLACEBO-CONTROLLED STUDY [J].
DUPONT, HL ;
ERICSSON, CD ;
MATHEWSON, JJ ;
DUPONT, MW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :87-91
[4]   A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea [J].
DuPont, HL ;
Jiang, ZD ;
Okhuysen, PC ;
Ericsson, CD ;
de la Cabada, FJ ;
Ke, S ;
DuPont, MW ;
Martinez-Sandoval, F .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (10) :805-812
[5]   Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci [J].
DuPont, HL ;
Jiang, ZD .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (11) :1009-1011
[6]   TREATMENT OF TRAVELERS DIARRHEA WITH TRIMETHOPRIM SULFAMETHOXAZOLE AND WITH TRIMETHOPRIM ALONE [J].
DUPONT, HL ;
REVES, RR ;
GALINDO, E ;
SULLIVAN, PS ;
WOOD, LV ;
MENDIOLA, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (14) :841-844
[7]  
DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507
[8]   Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: A randomized, double-blind clinical trial [J].
DuPont, HL ;
Jiang, ZD ;
Ericsson, CD ;
Adachi, JA ;
Mathewson, JJ ;
DuPont, MW ;
Palazzini, E ;
Riopel, LM ;
Ashley, D ;
Martinez-Sandoval, F .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1807-1815
[9]   Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers' diarrhea [J].
DuPont, HL ;
Ericsson, CD ;
Mathewson, JJ ;
Palazzini, E ;
DuPont, MW ;
Jiang, ZD ;
Mosavi, A ;
de la Cabada, FJ .
DIGESTION, 1998, 59 (06) :708-714
[10]  
Ericsson, 1997, J Travel Med, V4, P3, DOI 10.1111/j.1708-8305.1997.tb00765.x